RELATING TO FOOD AND DRUGS -- WHOLESALE PRESCRIPTION DRUG, IMPORTATION PROGRAM
S2387 would create a new Rhode Island Wholesale Prescription Drug Importation Program allowing the state, or a state-designated wholesaler, to import certain prescription drugs from Canada for distribution within Rhode Island. The program is intended to lower drug costs for consumers by bringing in only FDA-compliant medications expected to produce substantial savings. The bill directs the Executive Office of Health and Human Services to design the program in consultation with federal, state, and private stakeholders, and to ensure compliance with federal importation requirements.
The bill sets out a detailed framework for implementation. It requires the state to designate or contract with a licensed drug wholesaler, work with licensed Canadian suppliers, create a public website listing drug prices, establish consumer and stakeholder outreach, provide a hotline, and maintain an audit plan. It also requires annual reporting to legislative leaders on participating entities, drugs dispensed, estimated savings, and audit findings. The program cannot begin until the state receives approval and certification from the U.S. Department of Health and Human Services, and the bill directs the state to seek that approval by May 1, 2027.
If enacted, the bill would add a new chapter to Title 21 of the Rhode Island General Laws governing wholesale prescription drug importation. It would authorize state involvement in importing prescription drugs from Canada, but only within the limits of federal law and only after federal approval and certification. The measure would affect the Executive Office of Health and Human Services, a designated state agency or contracted wholesaler, pharmacies, health insurers, employers, providers, and consumers by creating a new state-run importation and distribution structure aimed at reducing prescription drug costs.
The bill’s stated purpose and structure suggest generally favorable sentiment toward lowering prescription drug prices and expanding consumer access to lower-cost medications. The bill is introduced by a group of senators and contains no recorded committee testimony or votes in the provided materials, so there is no documented opposition or support in the record beyond the bill text itself. Its emphasis on safety, federal compliance, and cost savings indicates an effort to frame the proposal as a consumer-protection and affordability measure rather than a broad market disruption.
The main points of potential contention are likely to be federal approval, drug safety, and implementation complexity. Because the program cannot operate without U.S. Department of Health and Human Services approval, opponents could question whether the state can realistically implement the program or achieve meaningful savings. Other likely concerns include the administrative burden on the state, the need to contract with wholesalers and Canadian suppliers, and whether the program can reliably meet federal tracing and transaction requirements. Supporters would likely focus on affordability, while skeptics may emphasize regulatory, legal, and operational risks.